NHS apologizes for lymphomas in transplant patients

"On behalf of NHSBT, I offer our sincere and unreserved apologies to the patients for the fact that each received a donated kidney that would have been rejected by their surgeon if he had been aware of the complete donor information."

This is part of the public apology offered by Lynda Hamlyn, chief executive of the NHS Blood and Transplant, after it came to light that two patients who received kidneys from the same deceased donor had developed the same subtype of non-Hodgkin's lymphoma, because the transplant team did not detect the cancer in the donor.

A 46 year old woman and a 59 year old man found out within a week or so of their kidney transplant procedure that the donor had intravascular B-cell lymphoma--and now, so did they.

Each patient required several rounds of combination chemotherapy. Each is currently considered cancer-free, but it is also something they will live with and worry about for the rest of their lives.

Source: UK Press Association

More Articles

More Articles

Amazon.com is pleased to have the Lymphoma Information Network in the family of Amazon.com associates. We've agreed to ship items...

The question ought to be what are myelodysplastic syndromes (MDS), since this is a group of similar blood and bone marrow diseases that...

Merkel Cell Carcinoma (MCC) is a very rare and aggressive skin cancer that usually develops when a person is in his or her 70s. It is...

Radiation Therapy Topics

...

At some point, the Seattle biotech company Cell Therapeutics Inc (CTI) should earn an entry in the Guinness Book of World Records for utter and...

Site Beginnings

This site was started as Lymphoma Resource Page(s) in 1994. The site was designed to collect lymphoma...

Three papers appearing in the journal Blood and pointing towards a regulator-suppressor pill could offer hope to blood cancer...

The US Food and Drug Administration (FDA) has granted a third so-called Breakthrough Therapy Designation for the investigational oral...

The US Food and Drug Administration today has approved an expanded use of Imbruvica (ibrutinib) in patients with...

The U.S. Food and Drug Administration has announced that it has granted "Breakthrough Therapy Designation" for the investigational agent...

According to a new study published in the Proceedings of the National Academy of Sciences, a team from the University of California, San...

Pharmacyclics has announced that the company has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for...

New research suggests that frontline radioimmunotherapy...

Gilead Sciences has announced results of the company's Phase II study of its investigational compound idelalisib, an oral inhibitor of...

Sitemap